Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground.
The blood–brain barrier (BBB) is meant to protect the brain from noxious agents; however, it also significantly hinders the delivery of therapeutics to the brain. Several strategies have been employed ...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the ...
A venture-backed biotechnology company developing blood-brain barrier (BBB)–penetrant antibody therapies for neurodegenerative diseases, starting with Alzheimer’s disease. Korsana’s strategy is built ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm Phase 1/2 study; sustained ...
Results from a pilot clinical trial evaluating the safety and feasibility of repeated focused ultrasound-induced blood–brain barrier (BBB) opening combined with the monoclonal antibody drug Avastin ...
However, emerging research indicates that this sweetener may pose significant risks to brain health, particularly by compromising the blood-brain barrier. This article delves into the findings of ...
When faced with chronic stress, why do some people develop anxiety and depressive symptoms while others show resilience? The results of studies in mice, headed by researchers at Université Laval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results